This global effort will help put the IsoFlow™ into the hands of as many physicians as possible. Crowdfunding through Indiegogo lets individuals world-wide participate in this global effort to help others in their fight against cancer. - Robert Goldman, CEO
San Jose, CA (PRWEB) October 17, 2016
Vascular Designs, a medical device company located in San Jose, CA, today announced that it is launching a crowdfunding campaign to increase availability to patients of its’ FDA 510(k) cleared IsoFlow™ infusion catheter. The IsoFlow™ allows for the direct delivery of medications into highly targeted areas. An important application of IsoFlow™ may be in the treatment of cancer. Part of the money raised will be used for additional IsoFlow™ configurations, which will expand treatment locations and provide additional options to physicians. To participate in the campaign, please visit http://www.vasculardesigns.com.
The IsoFlow™ Infusion catheter enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. There have already been a number of patients who have been treated using IsoFlow’s™ direct treatment approach. With IsoFlow's™ unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy.*
“This global effort will help put the IsoFlow™ into the hands of as many physicians as possible. Crowdfunding through Indiegogo lets individuals world-wide participate in this global effort to help others in their fight against cancer,” says CEO and founder, Robert Goldman.
The crowdfunding campaign is timed to coincide with the start of the holiday season. ‘Thinking of You’ holiday cards are being offered as a perk for backing the campaign. These beautifully designed cards will be sent to those who are currently fighting the courageous battle against cancer or to honor the memory of a lost loved one.
"IsoFlow™ could have a huge impact on the way many of today's deadliest illnesses such as cancer are treated. This method of local delivery may cause tumors that were previously unresponsive to systemic chemotherapy to respond. Additionally, the IsoFlow™ catheter may be able to provide treatment for a number of other medical conditions for which local delivery would be an ideal option," continued Goldman. "The potential applications of IsoFlow™ are exciting. We are looking forward to seeing how physicians will leverage this breakthrough catheter medical device into practice and the impact that it will surely make on the prognosis of so many patients."
The crowdfunding campaign will run for the next 30 days. For more information on Vascular Designs or to participate in this world-wide effort to help cancer patients, please visit http://www.vasculardesigns.com.
About Vascular Designs
Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ infusion catheter. His personal experience of watching loved ones suffer from and succumb to cancer had a profound influence on the creation of IsoFlow™. Vascular Designs has received FDA 510(k) marketing clearance for IsoFlow™, which enables the direct delivery of medications into targeted areas. An important application for the IsoFlow™ catheter may be in the treatment of cancer. IsoFlow™ enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With the IsoFlow™ catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.
For more information about Vascular Designs, please visit http://www.vasculardesigns.com or by email at wecare(at)vasculardesigns(dot)com.
- Chrysos, E., et al. Treatment of Unrescectable Malignant Abdominal, Pelvic and Thoracic Tumors Using Abdominal Pelvic and Thoracic Stop-flow Chemotherapy. Anticancer Research, Sept.-Oct. 2001. 21(5):3669-3675.
Collins, J.M., Pharmacologic Rationale for Regional Drug Delivery. Journal of Clinical Oncology, Vol. 2, 498-504. 1984.
Lygidakis, N.J., Sgourakis, G. and Aphinives, P. Upper Abdominal Stop-flow Perfusion as a Neo and Adjuvant Hypoxic Regional Chemotherapy for Resectable Gastric Carcinoma: A Prospective Randomized Clinical Trial. Hepatogastroenterology, May-Jun. 1999. 46(27): 2035-2038.
Miotto, D., et al. Hypoxic Antiblastic Stop-flow Perfusion: Clinical Outcome and Pharmacokinetic Findings. Journal of Chemotherapy, Nov. 16, 2004. Suppl. 5: 44-47.
Pilati, P., et al. Stop-flow Technique for Loco-regional Delivery of Antiblastic Agents: Literature Review and Personal Experience. European Journal of Surgical Oncology, Aug. 28, 2002. 544-553.